Publication

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Journal Paper/Review - Jan 1, 2016

Units
Keywords
PubMed
Doi
Link
Contact

Citation
Diem S, Keller F, Rüesch R, Maillard S, Speiser D, Dummer R, Siano M, Urner-Bloch U, Goldinger S, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.
Project
Type
Journal Paper/Review (English)
Journal
J Immunother 2016; 39
Publication Date
Jan 1, 2016
Issn Print
Issn Electronic
1537-4513
Pages
379-382
Publisher
Brief description/objective

UNASSIGNED
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.